Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...
Systems (NASDAQ: KRMD), a medical technology firm with a market capitalization of $194 million, announced a partnership with a global pharmaceutical manufacturer to conduct a Phase III clinical trial.
A Nashville infusion therapy company has quietly opened a flurry of D.C.-area locations within the past few months — and intends to bring more to the market this year.